Clinical Trial Update: A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) [Phase 4]

View source ↗

Summary

This Phase 4 study evaluated esomeprazole 40 mg once daily for GERD symptoms in patients who had prior full-dose proton pump inhibitor therapy; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Nexium (esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease | Phase 4 | Status: COMPLETED | Results posted: 2012-10-10